U.S., April 7 -- ClinicalTrials.gov registry received information related to the study (NCT07512362) titled 'Human Mesenchymal Stem Cells & Monoclonal Antibodies in the Treatment for Mild Cognitive Impairment or Early Alzheimer's Disease.' on March 23.
Brief Summary: The purpose of this study is to test if adding one infusion of (Human Mesenchymal Stem Cells) hMSCs to the treatment with standard of care (SOC) monoclonal antibodies (mAb) will stabilize the rate of cognitive and functional decline associated with mild Alzheimer's Disease.
Study Start Date: June 15
Study Type: INTERVENTIONAL
Condition:
Mild Cognitive Impairment
Early Alzheimer's Disease
AD-MCI
Intervention:
BIOLOGICAL: human Mesenchymal Stem Cells
Patients eligible to ...